A5036151830- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Viral Infectious Diseases and Gene Expression in Insects
- T-cell and B-cell Immunology
- Hepatitis B Virus Studies
- Biosimilars and Bioanalytical Methods
- Viral Infections and Vectors
- Liver Disease Diagnosis and Treatment
- Animal Virus Infections Studies
- Herpesvirus Infections and Treatments
- interferon and immune responses
- Cancer Research and Treatments
- Hepatitis C virus research
- Yersinia bacterium, plague, ectoparasites research
Universidad de Navarra
2005-2024
Navarre Institute of Health Research
2017-2024
Clinica Universidad de Navarra
2024
Recent studies have found that tumor-infiltrating lymphocytes (TIL) expressing PD-1 can recognize autologous tumor cells, suggesting cells derived from PD-1+ TILs be used in adoptive T-cell therapy (ACT). However, no study thus far has evaluated the antitumor activity of PD-1-selected vivo In two mouse models solid tumors, we show allows identification and isolation tumor-specific without previous knowledge their antigen specificities. Importantly, despite high proportion tumor-reactive T...
Target antigen (Ag) loss has emerged as a major cause of relapse after chimeric receptor T (CART)-cell therapy. We reasoned that the combination CART cells, with consequent tumor debulking and release Ags, together an immunomodulatory agent, such stimulator interferon gene ligand (STING-L) 2'3'-cyclic GMP-AMP (2'3'-cGAMP), may facilitate activation endogenous response to secondary Ags able counteract this escape mechanism.Mice bearing B16-derived tumors expressing prostate-specific membrane...
Abstract NK‐cell reactivity against cancer is conceivably suppressed in the tumor microenvironment by interaction of inhibitory receptor NKG2A with non‐classical MHC‐I molecules HLA‐E humans or Qa‐1 b mice. We found that intratumoral delivery NK cells attains significant therapeutic effects only if co‐injected anti‐NKG2A and anti‐Qa‐1 blocking monoclonal antibodies solid mouse models. Such activity was contingent on endogenous CD8 T type‐1 conventional dendritic (cDC1). Moreover, anti‐tumor...
Abstract Background Adoptive immunotherapy with tumour-infiltrating lymphocytes (TIL) may benefit from the use of selective markers, such as PD-1, for tumour-specific T-cell enrichment, and identification predictive factors that help identify those patients capable rendering tumour-reactive TILs. We have investigated this in ovarian cancer (OC) candidates TIL therapy implementation. Methods PD-1 − + CD8 TILs were isolated tumours expanded cells tested against autologous tumour cells....
Regulatory T cells overwhelm conventional in the tumor microenvironment (TME) thanks to a FOXP3-driven metabolic program that allows them engage different pathways. Using melanoma model of adoptive cell therapy (ACT), we show FOXP3 overexpression mature CD8 improved their antitumor efficacy, favoring recruitment, proliferation, and cytotoxicity. FOXP3-overexpressing (Foxp3UP) exhibited features tissue-resident memory-like effector cells, but not suppressor activity. Transcriptomic analysis...
Glypican-3 (GPC3) is a promising target for T-cell therapy in hepatocellular carcinoma (HCC). While chimeric antigen receptor (CAR) T cells targeting GPC3 have demonstrated therapeutic efficacy, their effectiveness limited by challenges such as low persistence and shedding of surface GPC3. Natural receptors (TCRs) may serve an alternative, though identifying GPC3-specific TCRs within the endogenous repertoire difficult.
Systems for in vitro culture of Hepatitis C virus (HCV) are essential tools to analyse virus–cell interactions and investigate relevant pathophysiological aspects HCV infection. Although the replicon methodology has increased our understanding biology, this system does not reproduce natural Recently, tupaia ( Tupaia belangeri chinensis ) hepatocytes have been utilized HCV. In present work, primary infected with were used evolution quasispecies cells ability influence antiviral...
Abstract Background: Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) may benefit from the use of selective markers, such as programmed cell death protein 1 (PD-1), for tumor-specific T-cell enrichment, well predictive biomarkers that help identify those patients capable rendering tumor-reactive TIL products. We have investigated this in ovarian cancer (OC) candidate therapy implementation. Methods: PD-1 - and + CD8 TILs were isolated resected tumors and, after polyclonal...
<div>Abstract<p>Recent studies have found that tumor-infiltrating lymphocytes (TIL) expressing PD-1 can recognize autologous tumor cells, suggesting cells derived from PD-1<sup>+</sup> TILs be used in adoptive T-cell therapy (ACT). However, no study thus far has evaluated the antitumor activity of PD-1–selected <i>in vivo</i>. In two mouse models solid tumors, we show allows identification and isolation tumor-specific without previous knowledge their...
<p>Supplementary Figures: (Fig. S1) Multi-parametric flow cytometric analysis of tumor-infiltrating T lymphocyte subsets from freshly excised MC38 tumors; S2) Expression co-inhibitory and co-stimulatory molecules over the course tumor progression; S3) Tumor-reactivity CD137+ PD-1+ TILs, after isolation tumors in vitro expansion; S4) Kinetic expansion different CD8 TIL isolated S5) CDR3 spectratype analysis. Supplementary Tables: (Table Number fragments which dominance hierarchy changed...
<p>Supplementary Figures: (Fig. S1) Multi-parametric flow cytometric analysis of tumor-infiltrating T lymphocyte subsets from freshly excised MC38 tumors; S2) Expression co-inhibitory and co-stimulatory molecules over the course tumor progression; S3) Tumor-reactivity CD137+ PD-1+ TILs, after isolation tumors in vitro expansion; S4) Kinetic expansion different CD8 TIL isolated S5) CDR3 spectratype analysis. Supplementary Tables: (Table Number fragments which dominance hierarchy changed...
<div>Abstract<p>Recent studies have found that tumor-infiltrating lymphocytes (TIL) expressing PD-1 can recognize autologous tumor cells, suggesting cells derived from PD-1<sup>+</sup> TILs be used in adoptive T-cell therapy (ACT). However, no study thus far has evaluated the antitumor activity of PD-1–selected <i>in vivo</i>. In two mouse models solid tumors, we show allows identification and isolation tumor-specific without previous knowledge their...